Ann: 2020 Half Year Media Release, page-2

Reported revenues of $227.2m, down 17% on 1HFY19
• Reported EBITDA of $34.6m, a decrease of 47% on 1HFY19
• Underlying EBITDA of $47.4m, a decrease of 42% on 1HFY19
• Reported net loss after tax of $17.5m driven by lower earnings and restructuring expenses
• Net operating cashflow of $46.2m down 14% on 1HFY19
• Licensed novel oral contraceptive E4/DRSP in the US
• Generic NUVARING® complete response letter submitted to the US Food and Drug
Administration (FDA) with launch anticipated in CY20
• Filed three generic products with the FDA including a potential first-to-market women’s health
product
• Significant spend base reduction of $20m (annualised)